ZS consulting (Ed’s current job of nearly 15 years) has a valuation of approx $23B. Ed has also worked at places such as Eli Lilly (current market cap of $587B, although was probably more around $33B when he worked there), Bristol myers squibb - BMS (current market cap of $106B, approx $50B when he was there), Wyeth which was acquired by Pfizer for $68B back in 2009, plus more.
Now Ed has also gone out on his own and started his own advisory company. So it has left me wondering, why has he joined the team of a small $50M Aussie biotech such as Prescient? We are not just a client of his advisory company, he has joined our company! He is here to help progress PTX-100, so perhaps he see’s a big upside to be more closely associated with the company during this time?
The addition of Ed was announced by the company in last years March quarterly, why has he waited until now to promote it on his LinkedIn? Perhaps he has only just gotten around to it
He is a very well connected man, who has built a large network in the industry. Quite the addition to Prescient!
- Forums
- ASX - By Stock
- Daily happenings?.
ZS consulting (Ed’s current job of nearly 15 years) has a...
-
- There are more pages in this discussion • 212 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $32.21M |
Open | High | Low | Value | Volume |
4.1¢ | 4.3¢ | 4.0¢ | $29.44K | 697.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 80711 | 4.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.2¢ | 38862 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 80711 | 0.041 |
13 | 956068 | 0.040 |
3 | 243333 | 0.039 |
7 | 511315 | 0.038 |
2 | 109000 | 0.037 |
Price($) | Vol. | No. |
---|---|---|
0.042 | 38862 | 6 |
0.043 | 963485 | 3 |
0.044 | 120777 | 2 |
0.047 | 86129 | 3 |
0.048 | 60000 | 2 |
Last trade - 12.51pm 13/11/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online